Ratings Ildong Pharmaceutical Co., Ltd.

Equities

A249420

KR7249420001

End-of-day quote Korea S.E. Other stock markets 03:30:00 10/05/2024 am IST			5-day change	1st Jan Change
15,440 ^KRW	-1.40%		-0.77%	-14.98%

2023	Il Dong Pharmaceutical Eyes Approval for to Manufacture Japan's COVID-19 Treatment in South Korea	MT
2023	Il Dong Pharmaceutical Introduces New R&D Unit Yunovia	MT

Strengths

The company's attractive earnings multiples are brought to light by a P/E ratio at 11.17 for the current year.
The company has a low valuation given the cash flows generated by its activity.
For several months, analysts have been revising their EPS estimates roughly upwards.

Weaknesses

For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
ILDONG PHARMACEUTICAL CO., LTD.	-14.98%	315M	-	-
ELI LILLY AND COMPANY	+30.38%	684B		C+
NOVO NORDISK A/S	+26.51%	568B		B
JOHNSON & JOHNSON	-4.36%	361B		C+
MERCK & CO., INC.	+19.30%	329B		B-
ABBVIE INC.	+3.73%	284B		C+
ASTRAZENECA PLC	+16.70%	240B		B+
NOVARTIS AG	+8.78%	208B		B-
ROCHE HOLDING AG	-7.93%	200B		A+
AMGEN INC.	+7.68%	166B		C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes